Logo Image
|Webcasts|November 14, 2019

Anti-Microbial Resistance and the Role of Vaccines

Author(s)SGS

This webcast will look at the scale of AMR, how CROs can assist in the development plan of new antimicrobials and where commercial development of new vaccines may be most effective. It will also provide insights and expert opinion on the potential success of antibacterial vaccination in controlling the rise of AMR and reducing the economic burden of infectious diseases. Live: Europe: Thursday, Nov. 14, 2019 at 3pm GMT | 4pm CET North America: Thursday, Nov. 21, 2019 at 11am EST | 10am CST | 8am PST On demand available after airing until Nov. 21, 2020. Register free

Register free: http://www.appliedclinicaltrialsonline.com/act_w/resistance

Event Overview:
The prospect of widespread antimicrobial resistance in the global community offers a world view where AMR takes us “…back to the dark ages of medicine” (D.Cameron,2014). Although there are global initiatives looking to promote better prescribing practice, to encourage innovative approaches to reversing AMR or to assist in the development of new classes of antibiotics, the role of vaccination in controlling community carriage and spread of AMR strains is sometimes overlooked. This webinar will examine at the scale of AMR, how CROs can assist in the development plan of new antimicrobials and where commercial development of new vaccines may be most effective. It will also provide insights and expert opinion on the potential success of antibacterial vaccination in controlling the rise of AMR and reducing the economic burden of infectious diseases.

Key Learning Objectives:

  • The geographic spread of AMR and global threat to health, and its impact on prosperity

  • The scope of AMR interventions currently in operation and the roles of academia and commercial organizations (e.g., CROs) within them

  • Current antibacterial vaccines – successes and failures – hope for the future?

  • New approaches and targets in AMR control

  • Rolling out AMR vaccines – hurdles and barriers to success

Speakers: Professor Adam Cunningham, Professor of Functional Immunity at Institute of Immunology and Immunotherapy, Birmingham, UK

Adrian Wildfire, Scientific Director, SGS Life Sciences

Time and date: Europe: Thursday, Nov. 14, 2019 at 3pm GMT | 4pm CET

North America: Thursday, Nov. 21, 2019 at 11am EST | 10am CST | 8am PST

On demand available after airing until Nov. 21, 2020.

Sponsor: SGS

Register free: http://www.appliedclinicaltrialsonline.com/act_w/resistance

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more